🇺🇸 FDA
Pipeline program

TPIV200

16-011

Phase 2 mab completed

Quick answer

TPIV200 for Ovarian Cancer is a Phase 2 program (mab) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Marker Therapeutics
Indication
Ovarian Cancer
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials